1. Home
  2. ALLR vs SNAL Comparison

ALLR vs SNAL Comparison

Compare ALLR & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

HOLD

Current Price

$1.22

Market Cap

25.6M

Sector

Health Care

ML Signal

HOLD

Logo Snail Inc.

SNAL

Snail Inc.

HOLD

Current Price

$4.98

Market Cap

26.6M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLR
SNAL
Founded
2004
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
25.6M
26.6M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
ALLR
SNAL
Price
$1.22
$4.98
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$9.75
N/A
AVG Volume (30 Days)
101.8K
527.0K
Earning Date
05-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
120.00
EPS
N/A
N/A
Revenue
$320,000.00
$81,225,622.00
Revenue This Year
N/A
$15.53
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.77
$0.34
52 Week High
$2.35
$5.92

Technical Indicators

Market Signals
Indicator
ALLR
SNAL
Relative Strength Index (RSI) 46.26 70.54
Support Level $1.01 $0.65
Resistance Level $1.27 $5.92
Average True Range (ATR) 0.08 0.62
MACD 0.02 0.00
Stochastic Oscillator 69.51 60.28

Price Performance

Historical Comparison
ALLR
SNAL

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

About SNAL Snail Inc.

Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States. The Company has one operating and reportable segment. The company operates in the USA, the UK and Other Countries.

Share on Social Networks: